REAL-TIME FOLLOW-UP OF 5-FLUOROURACIL METABOLISM IN THE LIVER OF TUMOR PATIENTS BY MEANS OF F-19 MR SPECTROSCOPY

被引:54
作者
SEMMLER, W [1 ]
BACHERTBAUMANN, P [1 ]
GUCKEL, F [1 ]
ERMARK, F [1 ]
SCHLAG, P [1 ]
LORENZ, WJ [1 ]
VANKAICK, G [1 ]
机构
[1] UNIV HEIDELBERG,DEPT ONCOL SURG,W-6900 HEIDELBERG,GERMANY
关键词
Chemotherapy; Fluorine; Fluorouracil; Liver neoplasms; MR studies; 761.1214; Magnetic resonance (MR); spectroscopy; Metabolism;
D O I
10.1148/radiology.174.1.2104675
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Intraarterial 5-fluorouracil (5-FU) chemotherapy in eight patients, one with primary and seven with secondary liver tumors, was monitored by means of in vivo fluorine-19 magnetic resonance (MR) spectroscopy. F-19 MR spectra were obtained with surface coils and included signal contributions from both liver and tumor tissue. The time course of the relative concentrations of 5-FU and its major catabolite, α-fluoro-β-alanine (FBAL), was followed for up to 100 minutes after the start of drug administration. The time constants for the kinetics of 5-FU ranged from 8 to 75 minutes, whereas the time constants for FBAL were either approximately 15 or 50 minutes. A broad peak comprising nucleoside and nucleotide anabolites of 5-FU was detected in one patient. These investigations demonstrate the feasibility of short-term therapy monitoring with F-19 MR spectroscopy and that catabolites and anabolites of 5-FU can be observed separately. However, since no F-19 MR spectroscopy localization sequence is available at present, the contributions to the total MR signal from normal liver and tumor tissue cannot be discriminated.
引用
收藏
页码:141 / 145
页数:5
相关论文
共 22 条
[1]  
GLAHOLM J, 1988, SOC MAGNETIC RESONAN, V1, P351
[2]   INVIVO F-19-NMR OF 5-FLUOROURACIL INCORPORATION INTO RNA AND METABOLITES IN ESCHERICHIA-COLI-CELLS [J].
GOCHIN, M ;
JAMES, TL ;
SHAFER, RH .
BIOCHIMICA ET BIOPHYSICA ACTA, 1984, 804 (01) :118-124
[3]   FLUORINATED PYRIMIDINES, A NEW CLASS OF TUMOUR-INHIBITORY COMPOUNDS [J].
HEIDELBERGER, C ;
CHAUDHURI, NK ;
DANNEBERG, P ;
MOOREN, D ;
GRIESBACH, L ;
DUSCHINSKY, R ;
SCHNITZER, RJ ;
PLEVEN, E ;
SCHEINER, J .
NATURE, 1957, 179 (4561) :663-666
[4]  
HULL WE, 1988, CANCER RES, V48, P1680
[5]  
HULL WE, 1986, SOC MAGNETIC RESONAN, V3, P594
[6]  
HULL WE, 1987, J CANCER RES CLIN, V113, P46
[7]  
KOUTCHER JA, 1988, SOC MAGNETIC RESONAN, V1, P329
[8]  
MALETMARTINO MC, 1983, BIOMED PHARMACOTHER, V37, P357
[9]  
MALETMARTINO MC, 1986, CANCER RES, V46, P2105
[10]  
MALETMARTINO MC, 1986, CANCER CHEMOTH PHARM, V18, P5, DOI 10.1007/BF00253054